Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.580
+0.050 (3.27%)
At close: Dec 20, 2024, 4:00 PM
1.540
-0.040 (-2.53%)
After-hours: Dec 20, 2024, 4:46 PM EST
Heron Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Heron Therapeutics stock have an average target of 5.67, with a low estimate of 4.00 and a high estimate of 7.00. The average target predicts an increase of 258.86% from the current stock price of 1.58.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for HRTX stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +153.16% | Dec 4, 2024 |
| Needham | Needham | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +153.16% | Nov 13, 2024 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +216.46% | Sep 25, 2024 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +216.46% | Aug 7, 2024 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +343.04% | Jun 13, 2024 |
Financial Forecast
Revenue This Year
143.69M
from 127.04M
Increased by 13.10%
Revenue Next Year
170.65M
from 143.69M
Increased by 18.76%
EPS This Year
-0.13
from -0.80
EPS Next Year
-0.03
from -0.13
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 148.8M | 183.8M | 230.0M | |||
| Avg | 143.7M | 170.7M | 209.5M | |||
| Low | 137.2M | 158.8M | 188.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 17.1% | 27.9% | 34.7% | |||
| Avg | 13.1% | 18.8% | 22.8% | |||
| Low | 8.0% | 10.5% | 10.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.11 | - | 0.21 | ||
| Avg | -0.13 | -0.03 | 0.19 | ||
| Low | -0.14 | -0.05 | 0.17 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.